SILVER SPRING, Md. – Beating the odds, Orexigen Therapeutics Inc. won the backing of an FDA panel Tuesday for approval of the company's weight-loss drug Contrave (naltrexone/bupropion) – the only drug out of three recently reviewed at the agency to gain the Endocrinologic and Metabolic Drugs Advisory Committee's blessing.